Alnylam Pharmaceuticals - Cambridge, MA
posted about 1 month ago
We are looking for experienced Business Account Executives (BAEs) with rare disease experience to promote ONPATTRO® (patisiran) in the U.S. ONPATTRO was approved in August 2018 by the FDA for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis) in adults. The successful candidate will also have the opportunity to be part of the sales team responsible for the commercialization of Alnylam's second therapeutic in Alnylam's TTR portfolio, AMVUTTRA™. hATTR patients often spend years undiagnosed and misdiagnosed. This is an amazing opportunity to educate and enhance the market's knowledge of hATTR amyloidosis. The BAE (TTR BAE) will be principally responsible for driving physician and patient identification, disease awareness, overall market development, and brand awareness within their ascribed territory. The BAE will be responsible for achieving territory targets and other business objectives through account and customer strategies, while also partnering & collaborating very closely with internal and external stakeholders to effectively manage all aspects of the regional business. The achievement of targets will be based in Alnylam values: our commitment to people, sense of urgency, passion for excellence, innovation & discovery, and open culture as well as our unwavering commitment to integrity.